Biological approaches to improve skeletal muscle healing after injury and disease

Birth Defects Research Part C - Embryo Today: Reviews

Volumn 96, Issue 1, 2012, Pages 82-94

  Gharaibeh, Burhan ^a,b   Chun Lansinger, Yuri ^b   Hagen, Tanya ^b   Ingham, Sheila Jean McNeill ^a,b   Wright, Vonda ^b   Fu, Freddie ^b   Huard, Johnny ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin receptor blocker; Fibrosis; Losartan; Muscle derived stem cells; Muscle injury; Paracrine effect

Indexed keywords

LOSARTAN; LOSARTAN POTASSIUM; NERVE GROWTH FACTOR; SOMATOMEDIN C;

CELL THERAPY; FIBROSIS; GENETIC DISORDER; HAMSTRING; HEALING; HUMAN; IMMUNE RESPONSE; MUSCLE INJURY; MUSCLE REGENERATION; MYOBLAST; MYOSITIS; NONHUMAN; OXIDATIVE STRESS; PARACRINE SIGNALING; PRIORITY JOURNAL; REGENERATIVE ABILITY; REVIEW; SKELETAL MUSCLE; STEM CELL TRANSPLANTATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LOSARTAN; MUSCLE, SKELETAL; MUSCULAR DISEASES; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; PARACRINE COMMUNICATION; REGENERATION; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; STEM CELLS; TENDON INJURIES; TREATMENT OUTCOME; WOUND HEALING;

MURINAE;

EID: 84859113848     PISSN: 1542975X     EISSN: 15429768     Source Type: Journal    
DOI: 10.1002/bdrc.21005     Document Type: Review

References (154)

1. Allen RE, Boxhorn LK. 1989. Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor I, and fibroblast growth factor. J Cell Physiol 138: 311-315.
2. Almekinders LC. 1993. Anti-inflammatory treatment of muscular injuries in sports. Sports Med 15: 139-145.
3. Almekinders LC, Gilbert JA. 1986. Healing of experimental muscle strains and the effects of nonsteroidal antiinflammatory medication. Am J Sports Med 14: 303-308.
4. Amemiya K, Semino-Mora C, Granger RP, Dalakas MC. 2000. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 94: 99-104.
5. Anderson JE, Liu L, Kardami E. 1991. Distinctive patterns of basic fibroblast growth factor (bFGF) distribution in degenerating and regenerating areas of dystrophic (mdx) striated muscles. Dev Biol 147: 96-109.
6. Askling CM, Tengvar M, Saartok T, Thorstensson A. 2007. Acute first-time hamstring strains during slow-speed stretching: clinical, magnetic resonance imaging, and recovery characteristics. Am J Sports Med 35: 1716-1724.
7. Askling CM, Tengvar M, Saartok T, Thorstensson A. 2008. Proximal hamstring strains of stretching type in different sports: injury situations, clinical and magnetic resonance imaging characteristics, and return to sport. Am J Sports Med 36: 1799-1804.
8. Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. 1994. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest 93: 892-899.
9. Barnard W, Bower J, Brown MA, et al. 1994. Leukemia inhibitory factor (LIF) infusion stimulates skeletal muscle regeneration after injury: injured muscle expresses lif mRNA. J Neurol Sci 123: 108-113.
10. Barnes JL, Abboud HE. 1993. Temporal expression of autocrine growth factors corresponds to morphological features of mesangial proliferation in Habu snake venom-induced glomerulonephritis. Am J Pathol 143: 1366-1376.
11. Baroffio A, Hamann M, Bernheim L, et al. 1996. Identification of self-renewing myoblasts in the progeny of single human muscle satellite cells. Differentiation 60: 47-57.
12. Barton-Davis ER, Shoturma DI, Musaro A, et al. 1998. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA 95: 15603-15607.
13. Beauchamp JR, Morgan JE, Pagel CN, Partridge TA. 1999. Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. J Cell Biol 144: 1113-1122.
14. Bedair HS, Karthikeyan T, Quintero A, et al. 2008. Angiotensin II receptor blockade administered after injury improves muscle regeneration and decreases fibrosis in normal skeletal muscle. Am J Sports Med 36: 1548-1554.
15. Bernasconi P, Torchiana E, Confalonieri P, et al. 1995. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 96: 1137-1144.
16. Biressi S, Rando TA. 2010. Heterogeneity in the muscle satellite cell population. Semin Cell Dev Biol 21: 845-854.
17. Bondesen BA, Mills ST, Kegley KM, Pavlath GK. 2004. The COX-2 pathway is essential during early stages of skeletal muscle regeneration. Am J Physiol Cell Physiol 287: C475-C483.
18. Bondesen BA, Mills ST, Pavlath GK. 2006. The COX-2 pathway regulates growth of atrophied muscle via multiple mechanisms. Am J Physiol Cell Physiol 290: C1651-C1659.
19. Brandes ME, Allen JB, Ogawa Y, Wahl SM. 1991. Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 87: 1108-1113.
20. Brooks JH, Fuller CW, Kemp SP, Reddin DB. 2006. Incidence, risk, and prevention of hamstring muscle injuries in professional rugby union. Am J Sports Med 34: 1297-1306.
21. Burks TN, Cohn RD. 2011. Role of TGF-beta signaling in inherited and acquired myopathies. Skelet Muscle 1: 19-32.
22. Burks TN, Andres-Mateos E, Marx R, et al. 2011. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci Transl Med 3: 82ra37.
23. Carling C, Le Gall F, Orhant E. 2011. A four-season prospective study of muscle strain reoccurrences in a professional football club. Res Sports Med 19: 92-102.
24. Cerletti M, Jurga S, Witczak CA, et al. 2008. Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. Cell 134: 37-47.
25. Chambers RL, McDermott JC. 1996. Molecular basis of skeletal muscle regeneration. Can J Appl Physiol 21: 155-184.
26. Chan YS, Li Y, Foster W, et al. 2003. Antifibrotic effects of suramin in injured skeletal muscle after laceration. J Appl Physiol 95: 771-780.
27. Chan YS, Li Y, Foster W, et al. 2005. The use of suramin, an antifibrotic agent, to improve muscle recovery after strain injury. Am J Sports Med 33: 43-51.
28. Chen J, Park HC, Addabbo F, et al. 2008. Kidney-derived mesenchymal stem cells contribute to vasculogenesis, angiogenesis and endothelial repair. Kidney Int 74: 879-889.
29. Cohn RD, van Erp C, Habashi JP, et al. 2007. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13: 204-210.
30. Coimbra T, Wiggins R, Noh JW, et al. 1991. Transforming growth factor-beta production in anti-glomerular basement membrane disease in the rabbit. Am J Pathol 138: 223-234.
31. Coleman ME, DeMayo F, Yin KC, et al. 1995. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem 270: 12109-12116.
32. Collins C, Partridge T. 2005. Self-renewal of the adult skeletal muscle satellite cell. Cell Cycle 4: 1338-1341.
33. Collins CA, Zammit PS, Ruiz AP, et al. 2007. A population of myogenic stem cells that survives skeletal muscle aging. Stem Cells 25: 885-894.
34. Confalonieri P, Bernasconi P, Cornelio F, Mantegazza R. 1997. Transforming growth factor-beta 1 in polymyositis and dermatomyositis correlates with fibrosis but not with mononuclear cell infiltrate. J Neuropathol Exp Neurol 56: 479-484.
35. Connell DA, Schneider-Kolsky ME, Hoving JL, et al. 2004. Longitudinal study comparing sonographic and MRI assessments of acute and healing hamstring injuries. AJR Am J Roentgenol 183: 975-984.
36. Crisco JJ, Jokl P, Heinen GT, et al. 1994. A muscle contusion injury model. Biomechanics, physiology, and histology. Am J Sports Med 22: 702-710.
37. Czaja MJ, Weiner FR, Flanders KC, et al. 1989. In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J Cell Biol 108: 2477-2482.
38. Damon SE, Haugk KL, Birnbaum RS, Quinn LS. 1998. Retrovirally mediated overexpression of insulin-like growth factor binding protein 4: evidence that insulin-like growth factor is required for skeletal muscle differentiation. J Cell Physiol 175: 109-120.
39. De Deyne PG, Kinsey S, Yoshino S, Jensen-Vick K. 2002. The adaptation of soleus and edl in a rat model of distraction osteogenesis: IGF-1 and fibrosis. J Orthop Res 20: 1225-1231.
40. Deasy BM, Jankowski RJ, Huard J. 2001. Muscle-derived stem cells: characterization and potential for cell-mediated therapy. Blood Cells Mol Dis 27: 924-933.
41. Deasy B, Gharaibeh B, Pollett J, et al. 2005. Long-term self-renewal of postnatal muscle-derived stem cells. Mol Cell Biol 16: 3323-3333.
42. Deasy BM, Feduska JM, Payne TR, et al. 2009. Effect of VEGF on the regenerative capacity of muscle stem cells in dystrophic skeletal muscle. Mol Ther 17: 1788-1798.
43. Doumit ME, Cook DR, Merkel RA. 1993. Fibroblast growth factor, epidermal growth factor, insulin-like growth factors, and platelet-derived growth factor-BB stimulate proliferation of clonally derived porcine myogenic satellite cells. J Cell Physiol 157: 326-332.
44. Drowley L, Okada M, Beckman S, et al. 2010. Cellular antioxidant levels influence muscle stem cell therapy. Mol Ther 18(10): 1865-1873.
45. Engert JC, Berglund EB, Rosenthal N. 1996. Proliferation precedes differentiation in IGF-I-stimulated myogenesis. J Cell Biol 135: 431-440.
46. Fakhfakh R, Lamarre Y, Skuk D, Tremblay JP. 2011. Losartan enhances the success of myoblast transplantation. Cell Transplant: [Epub ahead of print].
47. Fan Y, Maley M, Beilharz M, Grounds M. 1996. Rapid death of injected myoblasts in myoblast transfer therapy. Muscle Nerve 19: 853-860.
48. Fanbin M, Jianghai C, Juan L, et al. 2011. Role of transforming growth factor-beta1 in the process of fibrosis of denervated skeletal muscle. J Huazhong Univ Sci Technolog Med Sci 31: 77-82.
49. Florini JR, Ewton DZ, Falen SL, Van Wyk JJ. 1986. Biphasic concentration dependency of stimulation of myoblast differentiation by somatomedins. Am J Physiol 250: C771-C778.
50. Florini JR, Ewton DZ, Coolican SA. 1996. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev 17: 481-517.
51. Floss T, Arnold HH, Braun T. 1997. A role for FGF-6 in skeletal muscle regeneration. Genes Dev 11: 2040-2051.
52. Folland J, Leach B, Little T, et al. 2000. Angiotensin-converting enzyme genotype affects the response of human skeletal muscle to functional overload. Exp Physiol 85: 575-579.
53. Foster W, Li Y, Usas A, et al. 2003. Gamma interferon as an antifibrosis agent in skeletal muscle. J Orthop Res 21: 798-804.
54. Fukushima K, Badlani N, Usas A, et al. 2001. The use of an antifibrosis agent to improve muscle recovery after laceration. Am J Sports Med 29: 394-402.
55. Fulle S, Di Donna S, Puglielli C, et al. 2005. Age-dependent imbalance of the antioxidative system in human satellite cells. Exp Gerontol 40: 189-197.
56. Gharaibeh B, Lu A, Tebbets J, et al. 2008. Isolation of a slowly adhering cell fraction containing stem cells from murine skeletal muscle by the preplate technique. Nat Protoc 3: 1501-1509.
57. Gharaibeh B, Lavasani M, Cummins JH, Huard J. 2011. Terminal differentiation is not a major determinant for the success of stem cell therapy - cross-talk between muscle-derived stem cells and host cells. Stem Cell Res Ther 2: 31-43.
58. Gnecchi M, He H, Liang OD, et al. 2005. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11: 367-368.
59. Gospodarowicz D, Weseman J, Moran JS, Lindstrom J. 1976. Effect of fibroblast growth factor on the division and fusion of bovine myoblasts. J Cell Biol 70: 395-405.
60. Gowdak LH, Poliakova L, Wang X, et al. 2000. Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation 102: 565-571.
61. Gremmler B, Kunert M, Schleiting H, Ulbricht LJ. 2000. Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan. Eur J Heart Fail 2: 183-187.
62. Grounds MD. 1991. Towards understanding skeletal muscle regeneration. Pathol Res Pract 187: 1-22.
63. Guerette B, Asselin I, Skuk D, et al. 1997. Control of inflammatory damage by anti-LFA-1: increase success of myoblast transplantation. Cell Transplant 6: 101-107.
64. Gussoni E, Blau HM, Kunkel LM. 1997. The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat Med 3: 970-977.
65. Habashi JP, Doyle JJ, Holm TM, et al. 2011. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 332: 361-365.
66. Harrington MA, Daub R, Song A, et al. 1992. Interleukin 1 alpha mediated inhibition of myogenic terminal differentiation: increased sensitivity of Ha-ras transformed cultures. Cell Growth Differ 3: 241-248.
67. Hill M, Wernig A, Goldspink G. 2003. Muscle satellite (stem) cell activation during local tissue injury and repair. J Anat 203: 89-99.
68. Hodgetts SI, Beilharz MW, Scalzo AA, Grounds MD. 2000. Why do cultured transplanted myoblasts die in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4+ and CD8+ cells or Nk1.1+ cells. Cell Transplant 9: 489-502.
69. Hoffman EP, Brown RHJr, Kunkel LM. 1987. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.
70. Huard J, Bouchard JP, Roy R, et al. 1991. Myoblast transplantation produced dystrophin-positive muscle fibres in a 16-year-old patient with Duchenne muscular dystrophy. Clin Sci (Lond) 81: 287-288.
71. Huard J, Roy R, Guerette B, et al. 1994. Human myoblast transplantation in immunodeficient and immunosuppressed mice: evidence of rejection. Muscle Nerve 17: 224-234.
72. Huard J, Li Y, Fu FH. 2002. Muscle injuries and repair: current trends in research. J Bone Joint Surg Am 84-A: 822-832.
73. Huard J, Cao B, Qu-Petersen Z. 2003. Muscle-derived stem cells: potential for muscle regeneration. Birth Defects Res C Embryo Today 69: 230-237.
74. Inselburg J, Applebaum B. 1978. Proteins synthesized in minicells containing plasmid ColE1 and its mutants. J Bacteriol 133: 1444-1451.
75. Ito K, Hirao A, Arai F, et al. 2006. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 12: 446-451.
76. Jarvinen MJ, Lehto MU. 1993. The effects of early mobilisation and immobilisation on the healing process following muscle injuries. Sports Med 15: 78-89.
77. Jennische E. 1989. Sequential immunohistochemical expression of IGF-I and the transferrin receptor in regenerating rat muscle in vivo. Acta Endocrinol (Copenh) 121: 733-738.
78. Jin P, Rahm M, Claesson-Welsh L, et al. 1990. Expression of PDGF A-chain and beta-receptor genes during rat myoblast differentiation. J Cell Biol 110: 1665-1672.
79. Johnson SE, Allen RE. 1995. Activation of skeletal muscle satellite cells and the role of fibroblast growth factor receptors. Exp Cell Res 219: 449-453.
80. Jones JI, Clemmons DR. 1995. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3-34.
81. Kagami S, Border WA, Miller DE, Noble NA. 1994. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93: 2431-2437.
82. Karpati G, Pouliot Y, Zubrzycka-Gaarn E, et al. 1989. Dystrophin is expressed in mdx skeletal muscle fibers after normal myoblast implantation. Am J Pathol 135: 27-32.
83. Keller HL, St Pierre Schneider B, Eppihimer LA, Cannon JG. 1999. Association of IGF-I and IGF-II with myofiber regeneration in vivo. Muscle Nerve 22: 347-354.
84. Khalil N, Whitman C, Zuo L, et al. 1993. Regulation of alveolar macrophage transforming growth factor-beta secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. J Clin Invest 92: 1812-1818.
85. Kinoshita I, Vilquin JT, Guerette B, et al. 1994. Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle Nerve 17: 1407-1415.
86. Kobayashi T, Uehara K, Ota S, et al. in press. The timing of Losartan administration represents a major determinant for the improvement of skeletal muscle healing after injury. J Appl Physiol.
87. Kurek JB, Bower JJ, Romanella M, et al. 1997. The role of leukemia inhibitory factor in skeletal muscle regeneration. Muscle Nerve 20: 815-822.
88. Lamberts SW, van den Beld AW, van der Lely AJ. 1997. The endocrinology of aging. Science 278: 419-424.
89. Lavasani M, Lu A, Peng H, et al. 2006. Nerve growth factor improves the muscle regeneration capacity of muscle stem cells in dystrophic muscle. Hum Gene Ther 17: 180-192.
90. Lee CW, Fukushima K, Usas A, et al. 2000. Biological intervention based on cell and gene therapy to improve muscle healing after laceration. J Musculoskel Res 4: 265.
91. Lee S, Shin HS, Shireman PK, et al. 2006. Glutathione-peroxidase-1 null muscle progenitor cells are globally defective. Free Radic Biol Med 41: 1174-1184.
92. Lefaucheur JP, Sebille A. 1995. Muscle regeneration following injury can be modified in vivo by immune neutralization of basic fibroblast growth factor, transforming growth factor beta 1 or insulin-like growth factor I. J Neuroimmunol 57: 85-91.
93. Li Y, Huard J. 2002. Differentiation of muscle-derived cells into myofibroblasts in injured skeletal muscle. Am J Pathol 161: 895-907.
94. Li Y, Cummins J, Huard J. 2001. Muscle injury and repair. Curr Opin Orthop 12: 409-415.
95. Li Y, Foster W, Deasy BM, et al. 2004. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am J Pathol 164: 1007-1019.
96. Li Y, Negishi S, Sakamoto M, et al. 2005. The use of relaxin improves healing in injured muscle. Ann NY Acad Sci 1041: 395-397.
97. Lim DS, Lutucuta S, Bachireddy P, et al. 2001. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103: 789-791.
98. Linkhart TA, Clegg CH, Hauschika SD. 1981. Myogenic differentiation in permanent clonal mouse myoblast cell lines: regulation by macromolecular growth factors in the culture medium. Dev Biol 86: 19-30.
99. Logan A, Berry M, Gonzalez AM, et al. 1994. Effects of transforming growth factor beta 1 on scar production in the injured central nervous system of the rat. Eur J Neurosci 6: 355-363.
100. Mauro A. 1961. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 9: 493-495.
101. McFarland DC, Pesall JE, Gilkerson KK. 1993. The influence of growth factors on turkey embryonic myoblasts and satellite cells in vitro. Gen Comp Endocrinol 89: 415-424.
102. Mendell JR, Kissel JT, Amato AA, et al. 1995. Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med 333: 832-838.
103. Menetrey J, Kasemkijwattana C, Day CS, et al. 2000. Growth factors improve muscle healing in vivo. J Bone Joint Surg Br 82: 131-137.
104. Mishra DK, Friden J, Schmitz MC, Lieber RL. 1995. Anti-inflammatory medication after muscle injury. A treatment resulting in short-term improvement but subsequent loss of muscle function. J Bone Joint Surg Am 77: 1510-1519.
105. Morgan JE, Hoffman EP, Partridge TA. 1990. Normal myogenic cells from newborn mice restore normal histology to degenerating muscles of the mdx mouse. J Cell Biol 111: 2437-2449.
106. Moyer AL, Wagner KR. 2011. Regeneration versus fibrosis in skeletal muscle. Curr Opin Rheumatol 23: 568-573.
107. Murry CE, Reinecke H, Pabon LM. 2006. Regeneration gaps: observations on stem cells and cardiac repair. J Am Coll Cardiol 47: 1777-1785.
108. Musaro A, Giacinti C, Borsellino G, et al. 2004. Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc Natl Acad Sci USA 101: 1206-1210.
109. Negishi S, Li Y, Usas A, et al. 2005. The effect of relaxin treatment on skeletal muscle injuries. Am J Sports Med 33: 1816-1824.
110. Obremsky WT, Seaber AV, Ribbeck BM, Garrett WEJr. 1994. Biomechanical and histologic assessment of a controlled muscle strain injury treated with piroxicam. Am J Sports Med 22: 558-561.
111. Okuda S, Languino LR, Ruoslahti E, Border WA. 1990. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 86: 453-462.
112. Olson EN, Sternberg E, Hu JS, et al. 1986. Regulation of myogenic differentiation by type beta transforming growth factor. J Cell Biol 103: 1799-1805.
113. Onder G, Vedova CD, Pahor M. 2006. Effects of ACE inhibitors on skeletal muscle. Curr Pharm Des 12: 2057-2064.
114. Ota S, Uehara K, Nozaki M, et al. 2011. Intramuscular transplantation of muscle-derived stem cells accelerates skeletal muscle healing after contusion injury via enhancement of angiogenesis. Am J Sports Med 39: 1912-1922.
115. Otsuka M, Takahashi H, Shiratori M, et al. 2004. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 59: 31-38.
116. Paizis G, Gilbert RE, Cooper ME, et al. 2001. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 35: 376-385.
117. Papadakis MA, Grady D, Black D, et al. 1996. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 124: 708-716.
118. Payne TR, Oshima H, Sakai T, et al. 2005. Regeneration of dystrophin-expressing myocytes in the mdx heart by skeletal muscle stem cells. Gene Ther 12: 1264-1274.
119. Physicians AAoF. 2005. ICD-9 Codes for Family Medicine 2005-2006. Family Practice Management 12(8): 48A.
120. Pomeranz SJ, Heidt RSJr. 1993. MR imaging in the prognostication of hamstring injury. Work in progress. Radiology 189: 897-900.
121. Qu-Petersen Z, Deasy B, Jankowski R, et al. 2002. Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. J Cell Biol 157: 851-864.
122. Qu Z, Balkir L, van Deutekom JC, et al. 1998. Development of approaches to improve cell survival in myoblast transfer therapy. J Cell Biol 142: 1257-1267.
123. Quinn LS, Haugk KL. 1996. Overexpression of the type-1 insulin-like growth factor receptor increases ligand-dependent proliferation and differentiation in bovine skeletal myogenic cultures. J Cell Physiol 168: 34-41.
124. Santhanam AV, Smith LA, He T, et al. 2007. Endothelial progenitor cells stimulate cerebrovascular production of prostacyclin by paracrine activation of cyclooxygenase-2. Circ Res 100: 1379-1388.
125. Sato K, Li Y, Foster W, et al. 2003. Improvement of muscle healing through enhancement of muscle regeneration and prevention of fibrosis. Muscle Nerve 28: 365-372.
126. Seale P, Sabourin L, Girgis-Garbado A, et al. 2000. Pax7 is required for the specification of the myogenic satellite cells. Cell 102(6): 777-786.
127. Sheehan SM, Tatsumi R, Temm-Grove CJ, Allen RE. 2000. HGF is an autocrine growth factor for skeletal muscle satellite cells in vitro. Muscle Nerve 23: 239-245.
128. Shen W, Li Y, Tang Y, et al. 2005. NS-398, a cyclooxygenase-2-specific inhibitor, delays skeletal muscle healing by decreasing regeneration and promoting fibrosis. Am J Pathol 167: 1105-1117.
129. Shen W, Prisk V, Li Y, et al. 2006. Inhibited skeletal muscle healing in cyclooxygenase-2 gene-deficient mice: the role of PGE2 and PGF2alpha. J Appl Physiol 101: 1215-1221.
130. Slavotinek JP, Verrall GM, Fon GT. 2002. Hamstring injury in athletes: using MR imaging measurements to compare extent of muscle injury with amount of time lost from competition. Am J Roentgenol 179: 1621-1628.
131. Sporn MB, Roberts AB. 1993. A major advance in the use of growth factors to enhance wound healing. J Clin Invest 92: 2565-2566.
132. Springer ML, Chen AS, Kraft PE, et al. 1998. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell 2: 549-558.
133. Springer ML, Ozawa CR, Banfi A, et al. 2003. Localized arteriole formation directly adjacent to the site of VEGF-induced angiogenesis in muscle. Mol Ther 7: 441-449.
134. Suga S, Mazzali M, Ray PE, et al. 2002. Angiotensin II type 1 receptor blockade ameliorates tubulointerstitial injury induced by chronic potassium deficiency. Kidney Int 61: 951-958.
135. Swedberg K, Kjekshus J. 1988. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol 62: 60A-66A.
136. Tatsumi R, Anderson JE, Nevoret CJ, et al. 1998. HGF/SF is present in normal adult skeletal muscle and is capable of activating satellite cells. Dev Biol 194: 114-128.
137. Togel F, Weiss K, Yang Y, et al. 2007. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 292: F1626-F1635.
138. Urish KL, Vella JB, Okada M, et al. 2009. Antioxidant levels represent a major determinant in the regenerative capacity of muscle stem cells. Mol Biol Cell 20: 509-520.
139. Vilquin JT, Guerette B, Kinoshita I, et al. 1995. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther 6: 1391-1401.
140. Westergren-Thorsson G, Hernnas J, Sarnstrand B, et al. 1993. Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats. J Clin Invest 92: 632-637.
141. Wieteska-Skrzeczynska W, Grzelkowska-Kowalczyk K, Rejmak E. 2011a. Growth factor and cytokine interactions in myogenesis. Part II. Expression of IGF binding proteins and protein kinases essential for myogenesis in mouse C2C12 myogenic cells exposed to TNF-alpha and IFN-gamma. Pol J Vet Sci 14: 425-431.
142. Wieteska-Skrzeczynska W, Grzelkowska-Kowalczyk K, Tokarska J, Grabiec K. 2011b. Growth factor and cytokine interactions in myogenesis. Part I. The effect of TNF-alpha and IFN-gamma on IGF-I-dependent differentiation in mouse C2C12 myogenic cells. Pol J Vet Sci 14: 417-424.
143. Wolf YG, Rasmussen LM, Ruoslahti E. 1994. Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model. J Clin Invest 93: 1172-1178.
144. Woods C, Hawkins RD, Maltby S, et al. 2004. The Football Association Medical Research Programme: an audit of injuries in professional football-analysis of hamstring injuries. Br J Sports Med 38: 36-41.
145. Woolf AD, Pfleger B. 2003. Burden of major musculoskeletal conditions. Bull World Health Organ 81: 646-656.
146. Worrell TW. 1994. Factors associated with hamstring injuries. An approach to treatment and preventative measures. Sports Med 17: 338-345.
147. Wynn TA. 2007. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117: 524-529.
148. Yablonka-Reuveni Z, Balestreri TM, Bowen-Pope DF. 1990. Regulation of proliferation and differentiation of myoblasts derived from adult mouse skeletal muscle by specific isoforms of PDGF. J Cell Biol 111: 1623-1629.
149. Yamamoto T, Nakamura T, Noble NA, et al. 1993. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90: 1814-1818.
150. Yamazaki M, Minota S, Sakurai H, et al. 1994. Expression of transforming growth factor-beta 1 and its relation to endomysial fibrosis in progressive muscular dystrophy. Am J Pathol 144: 221-226.
151. Yoon CH, Hur J, Park KW, et al. 2005. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 112: 1618-1627.
152. Zammit P, Beauchamp J. 2001. The skeletal muscle satellite cell: stem cell or son of stem cell? Differentiation 68: 193-204.
153. Zanotti S, Negri T, Cappelletti et al. 2005. Decorin and biglycan expression is differentially altered in several muscular dystrophies. Brain 128(Pt 11): 2546-2555.
154. Zdanowicz MM, Moyse J, Wingertzahn MA, et al. 1995. Effect of insulin-like growth factor I in murine muscular dystrophy. Endocrinology 136: 4880-4886.